EBITDA Margin: Earnings before interest, taxes, depreciation and amortization as a portion of total revenue. Calculated as: EBITDA / Total Revenues
Foghorn Therapeutics Inc. (FHTX) had EBITDA Margin of -274.95% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$30.91M |
|
$-74.28M |
|
-- |
|
$30.91M |
|
$117.30M |
|
$-86.39M |
|
$12.11M |
|
$-74.28M |
|
$-74.28M |
|
$-74.28M |
|
$-74.28M |
|
$-74.28M |
|
$-74.28M |
|
$-86.39M |
|
$-84.98M |
|
62.98M |
|
62.98M |
|
$-1.18 |
|
$-1.18 |
|
| Balance Sheet Financials | |
$163.24M |
|
$1.92M |
|
$34.87M |
|
$198.10M |
|
$59.74M |
|
-- |
|
$246.87M |
|
$306.60M |
|
$-108.50M |
|
$-108.50M |
|
$-108.50M |
|
56.66M |
|
| Cash Flow Statement Financials | |
$-86.10M |
|
$112.04M |
|
$1.02M |
|
$57.16M |
|
$84.13M |
|
$26.96M |
|
$10.40M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.73 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-279.49% |
|
-279.49% |
|
|
EBITDA Margin |
-274.95% |
-240.33% |
|
-240.33% |
|
$-86.15M |
|
-- |
|
-- |
|
-- |
|
0.16 |
|
-- |
|
-- |
|
-- |
|
68.46% |
|
68.46% |
|
-37.50% |
|
68.46% |
|
$-1.92 |
|
$-1.37 |
|
$-1.37 |
|